272 related articles for article (PubMed ID: 31241767)
1. Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.
Li H; Kim C; Liu W; Zhu J; Chin K; Rodriguez-Canales J; Rodgers GP
Int J Cancer; 2020 Mar; 146(5):1346-1358. PubMed ID: 31241767
[TBL] [Abstract][Full Text] [Related]
2. Deletion of the olfactomedin 4 gene is associated with progression of human prostate cancer.
Li H; Rodriguez-Canales J; Liu W; Zhu J; Hanson JC; Pack S; Zhuang Z; Emmert-Buck MR; Rodgers GP
Am J Pathol; 2013 Oct; 183(4):1329-38. PubMed ID: 24070418
[TBL] [Abstract][Full Text] [Related]
3. Olfactomedin 4 deficiency promotes prostate neoplastic progression and is associated with upregulation of the hedgehog-signaling pathway.
Li H; Liu W; Chen W; Zhu J; Deng CX; Rodgers GP
Sci Rep; 2015 Nov; 5():16974. PubMed ID: 26581960
[TBL] [Abstract][Full Text] [Related]
4. Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma.
Duan C; Liu X; Liang S; Yang Z; Xia M; Wang L; Chen S; Yu L
J Cell Mol Med; 2014 May; 18(5):863-74. PubMed ID: 24495253
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
6. Olfactomedin 4 associates with expression of differentiation markers but not with properties of cancer stemness, EMT nor metastatic spread in colorectal cancer.
Jaitner S; Pretzsch E; Neumann J; Schäffauer A; Schiemann M; Angele M; Kumbrink J; Schwitalla S; Greten FR; Brandl L; Klauschen F; Horst D; Kirchner T; Jung A
J Pathol Clin Res; 2023 Jan; 9(1):73-85. PubMed ID: 36349502
[TBL] [Abstract][Full Text] [Related]
7. Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers.
Yu L; Wang L; Chen S
Neoplasma; 2011; 58(1):9-13. PubMed ID: 21067260
[TBL] [Abstract][Full Text] [Related]
8. Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
Sørensen KD; Borre M; Ørntoft TF; Dyrskjøt L; Tørring N
Int J Cancer; 2008 Feb; 122(3):509-19. PubMed ID: 17943724
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of SATB1 is associated with prostate cancer aggressiveness and disease progression.
Shukla S; Sharma H; Abbas A; MacLennan GT; Fu P; Danielpour D; Gupta S
PLoS One; 2013; 8(1):e53527. PubMed ID: 23308245
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.
Ma H; Tian T; Liang S; Liu X; Shen H; Xia M; Liu X; Zhang W; Wang L; Chen S; Yu L
Oncotarget; 2016 Mar; 7(9):10594-605. PubMed ID: 26871282
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of long non-coding RNA PlncRNA-1 promotes proliferation and induces epithelial-mesenchymal transition in prostate cancer.
Jin Y; Cui Z; Li X; Jin X; Peng J
Oncotarget; 2017 Apr; 8(16):26090-26099. PubMed ID: 28212533
[TBL] [Abstract][Full Text] [Related]
12. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
[TBL] [Abstract][Full Text] [Related]
13. Olfactomedin 4 mediation of prostate stem/progenitor-like cell proliferation and differentiation via MYC.
Li H; Chaitankar V; Zhu J; Chin K; Liu W; Pirooznia M; Rodgers GP
Sci Rep; 2020 Dec; 10(1):21924. PubMed ID: 33318499
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling.
Guo LL; He ZC; Yang CQ; Qiao PT; Yin GL
BMB Rep; 2015 Nov; 48(11):630-5. PubMed ID: 26303970
[TBL] [Abstract][Full Text] [Related]
15. DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer.
Zhang L; Zhang Q; Li L; Wang Z; Ying J; Fan Y; He Q; Lv T; Han W; Li J; Yang Y; Xu B; Wang L; Liu Q; Sun Y; Guo Y; Tao Q; Jin J
J Mol Med (Berl); 2015 Jun; 93(6):691-701. PubMed ID: 25648635
[TBL] [Abstract][Full Text] [Related]
16. Adiponectin as a potential tumor suppressor inhibiting epithelial-to-mesenchymal transition but frequently silenced in prostate cancer by promoter methylation.
Tan W; Wang L; Ma Q; Qi M; Lu N; Zhang L; Han B
Prostate; 2015 Aug; 75(11):1197-205. PubMed ID: 25877612
[TBL] [Abstract][Full Text] [Related]
17. MTSS1 hypermethylation is associated with prostate cancer progression.
Chen J; Huang L; Zhu Q; Wang Z; Tang Z
J Cell Physiol; 2020 Mar; 235(3):2687-2697. PubMed ID: 31541465
[TBL] [Abstract][Full Text] [Related]
18. Olfactomedin-4 in digestive diseases: A mini-review.
Wang XY; Chen SH; Zhang YN; Xu CF
World J Gastroenterol; 2018 May; 24(17):1881-1887. PubMed ID: 29740203
[TBL] [Abstract][Full Text] [Related]
19. Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer.
Liu W; Rodgers GP
Cancer Metastasis Rev; 2016 Jun; 35(2):201-12. PubMed ID: 27178440
[TBL] [Abstract][Full Text] [Related]
20. OLFM4 Inhibits Epithelial-Mesenchymal Transition and Metastatic Potential of Cervical Cancer Cells.
Li J; Liu C; Li D; Wan M; Zhang H; Zheng X; Jie X; Zhang P; Li J; Hou H; Sun Q
Oncol Res; 2019 Jul; 27(7):763-771. PubMed ID: 30764901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
